INFEPERIUM Trademark

Trademark Overview


On Monday, March 4, 2024, a trademark application was filed for INFEPERIUM with the United States Patent and Trademark Office. The USPTO has given the INFEPERIUM trademark a serial number of 98432261. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, September 19, 2024. This trademark is owned by Bal, Gary Gerard,. The INFEPERIUM trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical research
infeperium

General Information


Serial Number98432261
Word MarkINFEPERIUM
Filing DateMonday, March 4, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, September 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical research

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 11, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBal, Gary Gerard,
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressBoca Raton, FL 33434

Trademark Events


Event DateEvent Description
Thursday, March 7, 2024NEW APPLICATION ENTERED
Thursday, April 11, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 18, 2024ASSIGNED TO EXAMINER
Thursday, September 19, 2024NON-FINAL ACTION WRITTEN
Tuesday, December 17, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, December 17, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, September 19, 2024NON-FINAL ACTION E-MAILED
Thursday, September 19, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords


infeperium research medical